Inhibition of histone deacetylases: A pharmacological approach to the treatment of non-cancer disorders

Current Topics in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 257-271

  Wiech, Norbert L ^a   Fisher, Jed F ^b   Helquist, Paul ^b   Wiest, Olaf ^b  

^a Chromatin Therapeutics LLC   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; APICIDIN; BELINOSTAT; BML 210; BUTYRIC ACID; CD28 ANTIGEN; CD40 LIGAND; DEPSIPEPTIDE; GAMMA GLOBIN; HEMOGLOBIN F; HISTONE DEACETYLASE; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 10; M 344; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PLACEBO; ROMIDEPSIN; SK 7041; SURVIVAL MOTOR NEURON PROTEIN 2; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ABSENCE OF SIDE EFFECTS; ADRENOLEUKODYSTROPHY; AMYOTROPHIC LATERAL SCLEROSIS; BETA THALASSEMIA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOGENIC SHOCK; CARDIOTOXICITY; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION REGULATION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HEMORRHAGIC SHOCK; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; INFLAMMATORY DISEASE; MALARIA; MUSCULAR DYSTROPHY; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SICKLE CELL ANEMIA; SPINAL MUSCULAR ATROPHY; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THALASSEMIA; UNSPECIFIED SIDE EFFECT;

DRUG THERAPY; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS;

EID: 65449160927     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609788085241     Document Type: Review

References (148)

1. Spencer, V.; Davie, J. R. Role of covalent modifications of histones in regulating gene expression. Gene 1999, 240, 1-12.
2. Biel, M., Wascholowski, V.; Giannis, A. Epigenetics-an epicenter of gene regulation: Histones and histone-modifying enzymes. Angew. Chem. Int. Ed. 2005, 44, 3186-3216.
3. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349-352.
4. Wu, J.; Grunstein, M. 25 years after the nucleosome model: chromatin modifications. Trends Biochem. Sci. 2000, 25, 619-623.
5. Bolden, J. E.; Peart, M. J., Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Disc. 2006, 5, 769-784.
6. Gregoretti, L.; Lee, Y.; Goodson, H. V. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J. Mol. Biol. 2004, 17-31.
7. van Lint, C.; Emiliani, S.; Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996, 5, 245-253.
8. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X.; Mills, E.; Berghs, S. C.; Carey, N.; Finn, P. W.; Collins, L. S.; Tumber, A.; Ritchie, J. W.; Jensen, P. B.; Lichenstein, H. S.; Sehested, M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409, 581-589.
9. Bassel-Duby, R.; Olsen, E. N. Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem. 2006, 75, 19-37.
10. Yang, X.-J.; Gregoire, S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol. Cell Biol. 2005, 25, 2873-2884.
11. Riggs, M. J.; Whittaker, R. G.; Neumann, J. R.; Ingram, V. M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977, 268, 462-464.
12. Boffa, L. C.; Vidali, G.; Mann, R. S.; Allfrey, V. G. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J. Biol. Chem. 1978, 253, 3364-3366.
13. Prasad, K. N.; Sinha, P. K. Effect of sodium butyrate on mammalian cells in culture: a review. In Vitro 1976, 12, 125-132.
14. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
15. Fininin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V.; Rifkind, R.; Marks, P.; Breslow, R.; Pavletich, N. Structure of Histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
16. Glaser, K. B. HDAC inhibitors: Clinical update and mechanism-based potential. Biochem. Pharmacol. 2007, 74, 659-671.
17. Blackwell, L.; Norris, J.; Suto, C. M.; Janzen, W. P. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci. 2008, 82, 1050-1058.
18. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 2007, 25, 84-90.
19. Paris, D.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase Inhibitors: from bench to clinic. J. Med. Chem. 2008, 51, 1505-1529.
20. Weinmann, H.; Ottow, E. Recent advances in medicinal chemistry of histone deacetylase inhibitors. Ann. Rep. Med. Chem. 2004, 39, 185-196.
21. Kazantsev, A. G.; Thompson, L. M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7,854-868.
22. Krämer, O. H.; Göttlicher, M.; Heinzel, T. Histone deacetylase as a therapeutic target. Trends Endocr. Metab. 2001, 12, 294-300.
23. Reed, L. J.; Bradley, T. B.; Ranney, H. M. The effect of amelioration of anemia by the synthesis of fetal hemoglobin in sickle cell anemia. Blood 1965, 25, 37-43.
24. Wood, W. G.; Weatherall, D. J. Developmental genetics of the human hemoglobins. Biochem. J. 1983, 215, 1-9.
25. Perrine, S. P.; Faller, D. V.; Cohen, R.; Vichinsky, E. P.; Hurst, D.; Lubin, B. H.; Papayannopoulou, T. Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and β-thalassemia. Blood 1989, 74, 454-459.
26. Perrine, S. P.; Ginder, G. D.; Faller, D. V.; Dover, G. J.; Ikuta, T.; Witkowski, H. E.; Cai, S.-P.; Vichinsky, E. P.; Olivieri, N. F. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the expression in the β-globin disorders. N. Engl. J. Med. 1993, 328, 81-86.
27. Dover, G. J.; Brusilow, S. W.; Samid, D. Increased fetal hemoglobin in patients receiving sodium-4-phenylbutyrate. N. Engl. J. Med. 1992, 327, 569-570.
28. Dover, G.; Brusilow, S.; Charache, S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994, 84, 339-343.
29. Collins, A. F.; Pearson, H. A.; Giardina, P.; McDonagh, K. T.; Brusilow, S. W.; Dover, G. J. Oral sodium phenylbutyrate therapy in homozygous B-thalassemia: clinical trial. Blood 1995, 85, 43-49.
30. Collins, A. F.; Luban, N. L. C.; Dover, G. Increased fetal hemoglobin in patients receiving valproic acid for epilepsy. Blood 1994, 84, 1690-1691.
31. Selby, R.; Nisbet-Brown, E.; Basran, R. K.; Chang, L.; Olivieri, N. F. Valproic acid augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood 1997, 90, 891-893.
32. McCaffrey, P. G.; Newsome, D. A.; Fibach, E.; Yoshida, M.; Su, M. S.-S. Induction of gamma-globin by histone deacetylase inhibitors. Blood 1997, 90, 2075-2083.
33. Cao, H.; Stamatoyannopoulos, G. Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin. Am. J. Hematol. 2006, 81, 981-983.
34. Johnson, J.; Hunter, R.; McElveen, R.; Qian, X. H.; Baliga, B. S.; Pace, B. S. Fetal hemoglobin induction by the histone deacetylase inhibitor, scriptaid. Cell Mol. Biol. 2005, 51, 229-238.
35. Witt, O.; Mönkemeyer, G.; Rönndahl, G.; Erdlenbruch, B.; Reinhardt, D.; Kanbach, K.; Pekrun, A. Induction of fetal hemoglobin expression by histone deacetylase inhibitor apicidin. Blood 2003, 101, 2001-2007.
36. Wei, G. H.; Zhao, G. W.; Song, W.; Hao, D. L.; Lv, X.; Liu, D. P.; Liang, C. C. Mechanisms of human gamma-globin transcritpional induction by apicidin involves p38 signalling to chromatin. Biophs. Res. Commun. 2007, 363, 889-894.
37. Sangeman, J.; Lee, M. S.; Yao, X.; Oteng, E.; Hsiao, C. H.; Li, W.; Zein, S.; Ofori-Acquah, S. F.; Pace, B. Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves γ-globin activation by CREB1 and ATF-2. Blood 2006, 108, 3590-3599.
38. Hines, P.; Dover, G. J.; Resar, L. M. Pulsed-dosing with sodium phenylbutryrate increases Hemglobin F in a patient with sickle cell anemia. Pediatr. Blood Cancer 2007.
39. Fathallah, H.; Sutton, M.; Atweh, G. F. Pharmacological induction of fetal hemoglobin. Why haven't we been more successful in thalassemia?. Ann. N. Y. Acad. Sci. 2005, 1054, 228-237.
40. Rubenstein, R. C.; Zeitlin, P. L. In vitro pharamcologic restoration of CFTR-mediated chloride transport with sodium phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J. Clin. Invest. 1997, 100, 2457-2465.
41. Rubenstein, R. C.; Zeitlin, P. L. Sodium-4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of Delta F508CFTR. Am. J. Physiol. Cell Physiol. 2000, 278, C259-C267.
42. Rubenstein, R. C.; Zeitlin, P. L. A pilot clinical trial of sodium phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrotic patients: evidence of restoration of nasal epithelial CFTR function. Am. J. Resp. Crit. Care Med. 1998, 157, 484-490.
43. Wright, J. M.; Zeitlin, P. L.; Cebotaru, L.; Guggino, S. E.; Guggino, W. B. Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol. Genomics. 2004, 16, 204-211.
44. Singh, O. V.; Pollard, H. B.; Zeitlin, P. Chemical rescue of deltaF508-CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells. Mol. Cell Proteomics 2008, 7, 1099-1110.
45. Li, S.; Moy, L.; Pittman, N.; Shue, G.; Aufiero, B.; Neufeld, E. J.; LeLeiko, N. S.; Walsh, M. J. Transcriptional repression of the cystic fibrosis transmembrane conductance regulator gene, mediated by CCAAT displacement protein/cut homolog, is associated with histone deacetylation. J. Biol. Chem. 1999, 274, 7803-7815.
46. Paul, T.; Li, S.; Khurana, S.; Leliko, N. S.; Walsh, M. J. The epigenetic signature of CFTR expression is co-ordinated via chromatin acetylation through a complex intronic element. Biochem. J. 2007, 408, 317-326.
47. Kemp, S.; Wei, H.-M.; Lu, J.-F.; Braiterman, L. T.; McGuiness, M. C.; Moser, A.; Watkins, P. A.; Smith, K. D. Gene redundancy and pharamcological gene therapy: Implications for X-linked adrenoleukodystrophy. Nat. Med. 1999, 4, 1261-1268.
48. Wei, H.; Kemp, S.; McGuinness, M. C.; Moser, A. B.; Smith, K. D. Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann. Neurol. 2000, 47, 286-296.
49. Gondcaille, C.; Depreter, M.; Fourcade, S.; Lecca, M. R.; Leclerq, S.; Martin, P. G. P.; Pineau, T.; Cadepond, F.; ElEtr, M.; Bertrand, N. Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J. Cell Biol. 2005, 169, 93-104.
50. McGuiness, M. C.; Zhang, H.-P.; Smith, K. D. Evaluation of pharmacological induction of fatty acid oxidation in X-linked adrenoleukodystrophy. Mol. Gen. Met. 2001, 74, 256-263.
51. Iezzi, S.; Cossu, G.; Nervi, C.; Sartorelli, V.; Puri, P. L. Stage-specific modualtion of skeletal muscle myogenesis by inhibitors of nuclear deacetylases. Proc. Nat. Acad. Sci. 2002, 99, 7757-7762.
52. Iezzi, S.; Di Padova, M.; Serra, C.; Caretti, G.; Simone, C.; Maklan, E.; Minetti, G.; Zhao, P.; Hoffman, E. P.; Puri, P. L. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev. Cell 2004, 6, 673-684.
53. Minetti, G. C.; Colussi, C.; Adami, R.; Mozzetta, C.; Parente, V.; Fortuni, S.; Straino, S.; Sampaolesi, M.; Di Padova, M., I; lli, B. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 2006, 12, 1147-1150.
54. Panozzo, C.; Frugier, T.; Cifuentes-Diaz, C.; Melki, J. Spinal muscular atrophy. In: The Metabolic & Molecular Bases of Inherited Disease, Vol. IV. 8th ed 2001, Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Childs, B., Kinzler, K.W., Vogelstein, B. Eds., McGraw-Hill: New York, 5833-5843.
55. Chang, J.-G.; Hsieh-Li, H.-M.; Jong, Y.-J.; Wang, N. M.; Tsai, C.-H.; Li, H. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Nat. Acad. Sci. 2001, 98, 9808-9813.
56. Minamiyama, M.; Katsuno, M.; Adachi, H.; Waza, M.; Sang, C.; Kobayashi, Y.; Tanaka, F.; Doyu, M.; Inuki, A.; Sobue, G. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bubular muscular atrophy. Hum. Mol. Genet. 2004, 13, 1183-1192.
57. Brichta, L.; Hofmann, E.; Hahnen, E.; Siebzernrubl, F. A.; Raschke, H.; Blumcke, I.; Eyupoglu, I. Y.; Wirth, B. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Ann. Neurol. 2003, 59, 970-975.
58. Brichta, L.; Holker, I.; Haug, K.; Klockgetter, T.; Wirth, B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol. 2006, 59, 970-975.
59. Andreassi, C.; Angelozzi, C.; Tiziano, F. D.; Vitali, T.; De Vicenzi, E.; Boninsega, A.; Villanova, M.; Bertini, E.; Pinin, A.; Neri, G. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 2004, 12, 59-65.
60. Main, M.; Kairon, H.; Mercuri, E.; Muntoni, F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur. J. Paediatr. Neurol. 2003, 7, 155-159.
61. Mercuri, E.; Bertini, E.; Messina, S.; Pelliccioni, M.; D'Amico, A.; Colitto, F.; Mirabella, M.; Tiziano, F. D.; Vitali, T.; Angelozzi, C. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord. 2004, 14, 130-135.
62. Mercuri, E.; Bertini, E.; Messina, S.; Solari, A.; D'Amico, A.; Angelozzi, C.; Battini, R.; Berardelli, A.; Boffi, C.; Bruno, C. Randomized double-blind, palcebo controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007, 68, 51-55.
63. Riessland, M.; Brichta, L.; Hahnen, E.; Wirth, B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/ protein levels in spinal muscular atrophy cells. Hum. Genet. 2006, 120, 101-110.
64. Hahnen, E.; Eyupoglu, I. Y.; Haastert, K.; Trankle, C.; Siebzernrubl, F. A.; Riessland, M.; Holker, I.; Romstock, J.; Buslei, R.; Wirth, B. In vitro an ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. 2006, 98(1) 193-202.
65. Avila, A. M.; Burnett, B. G.; Taye, A. A.; Gabanella, F.; Knight, M. A.; Hartenstein, P.; Cizma, Z.; DiProspero, N. A.; Pellizzoni, L.; Fishbeck, K. H. Trichostatin A increases SMN expression and survival in a mose model of spinal muscular atrophy. J. Clin. Invest. 2007, 117, 659-671.
66. Narver, H. L.; Kong, L.; Burnett, B. G.; Choe, D. W.; Bosch-Marce, M.; Taye, A. A.; Eckhaus, M. A.; Sumner, C. J. Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition. Ann. Neurol. 2008, 64, 465-470.
67. Morrison, R. E.; Majdzadeh, N.; D'Mello, S. R. Histone deacetylases: Focus on the nervous system. Cell Mol. Life Sci. 2007, 64, 2258-2269.
68. Echaniz-Laguna, A.; Bousiges, O.; Loeffler, J.-P.; Boutllier, A.-L. Histone deacetylase inhibitors: Therapeutic agents and research tools for deciphering motor neuron diseases. Curr. Med. Chem. 2008, 15, 1263-1273.
69. Hayden, M. R.; Kremer, B. Huntington disease. In: The Metabolic & Molecular Bases of Inherited Disease, Vol. IV. 8th ed. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Childs, B., Kinzler, K.W., Vogelstein, B. Eds.; 2001, McGraw-Hill: New York, 5677-5701.
70. McCampbell, A.; Taye, A. A.; Whitty, L.; Penney, E.; Steffen, J. S.; Fishbeck, K. H. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Nat. Acad. Sci. 2001, 98, 15179-15184.
71. Steffan, J. S.; Bodal, L.; Pallos, J.; Poelman, M.; McCampbell, A.; Apostol, B. L.; Kazanstev, A.; Schmidt, E.; Zhu, Y.-Z.; Greenwald, M. Histone deacetylase inhibiotrs arrest polyglutamine-dependent neurodegeneration in Drosophilia. Nature 2001, 413, 739-743.
72. Ferrante, R. J.; Kubilus, J. K.; Lee, J.; Ryu, H.; Beesen, A.; Zucker, B.; Smith, K.; Kowall, N. W.; Ratan, R. R.; Luthi-Carter, R. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23, 9418-9427.
73. Gardian, G.; Browne, S. E.; Choi, D. K.; Klivenyi, P.; Gregorio, J.; Kubilus, J. K.; Ryu, H.; Langley, B.; Ratan, R. R.; Ferrante, R. J.; Beal, M. F. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280, 556-563.
74. Hockly, E.; Richon, V. M.; Woodman, B.; Smith, D. L.; Zhou, X.; Rosa, E.; Sathasivam, K.; Ghazi-Noori, S.; Mahal, A.; Lowden, P. A. S. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Nat Acad. Sci. 2003, 99, 7757-7762.
75. Dompierre, J. P.; Godin, J. D.; Charrin, B. C.; Cordelières, F. P.; King, S. J.; Humbert, S.; Saudou, F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 2007, 27, 3571-3583.
76. Sadri-Vakili, G.; Bouzou, B.; Benn, C. L.; Kim, M. O.; Chawla, P.; Overland, R. P.; Glajch, K. E.; Xia, E.; Qiu, Z.; Hersch, S. M. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 2007, 16, 1293-1306.
77. McKinsey, T. A.; Kuwahara, K.; Bezprozvannaya, S.; Olson, E. N. Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK. Mol. Biol. Cell 2006, 17, 438-447.
78. Lu, J.; McKinsey, T. A.; Olson, E. N. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc. Nat. Acad. Sci. 2000, 97, 4070-4075.
79. Gusterson, R. J.; Jazrawi, E.; Adcock, I. M.; Latchman, D. S. The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J. Biol. Chem. 2003, 278, 6838-6847.
80. Antos, C. L.; McKinsey, T. A.; Dreitz, M.; Hollingsworth, L. M.; Zhang, C. L.; Schreiber, K.; Rindt, H.; Gorczynski, R. J.; Olson, E. N. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 2003, 278, 28930-28937.
81. Kook, H.; Lepore, J. J.; Gitler, A. D.; Lu, M. M.; Yung, W. W.-M.; Mackay, J.; Zhou, R.; Ferrari, V.; Gruber, P.; Epstein, J. A. Cardiac hypertrophy and histone deacetylase-dependent transcritiptional repression mediated by the atypical homeodomain protein Hop. J. Clin. Invest. 2003, 112, 863-871.
82. Kong, Y.; Tannous, P.; Lu, G.; Berenji, K.; Rothermel, B. A.; Olson, E. N.; Hill, J. A. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006, 113, 2579-2588.
83. Kee, H. J.; Sohn, I. S.; Nam, K. I.; Park, J. E.; Qian, Y. R.; Yin, Z.; Ahn, Y.; Jeong, M. H.; Bang, Y. J.; Kim, N. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006, 113, 51-59.
84. Ren, M.; Leng, Y.; Jeong, M.; Leeds, P. R.; Chuang, D. M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 2004, 89, 1358-1367.
85. Faraco, G.; Pancani, T.; Formentini, L.; Mascagni, P.; Fossati, G.; Leoni, F.; Moroni, F.; Chiarugi, A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 2006, 70, 1876-1884.
86. Gonzales, E.; Chen, H.; Munuve, R.; Mehrani, T.; Britten-Webb, J.; Nadel, A.; Alam, H. B.; Wherry, D.; Burris, D.; Koustova, E. Valproic acid prevents hemorrhage-associated lethality and affects the acetylation pattern of cardiac histones. Shock 2006, 25, 395-401.
87. Lin, T.; Alam, H. B.; Chen, H.; Britten-Webb, J.; Rhee, P.; Kirkpatrick, J.; Koustova, E. Cardiac histones are substrates of histone deacetylase activity in hemorrhagic shock and resuscitation. Surgery 2006, 139, 365-376.
88. Zhao, T. C.; Cheng, G.; Zhang, L. X.; Tseng, Y. T.; Padbury, J. F. Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc. Res. 2007, 76, 473-481.
89. Sinn, D. I.; Kim, S. J.; Chu, K.; Jung, K. H.; Lee, S. T.; Song, E. C.; Kim, J. M.; Park, D. K.; Kun Lee, S.; Kim, M. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol. Dis. 2007, 26, 464-472.
90. Kim, H. J.; Rowe, M.; Ren, M.; Hong, J. S.; Chen, P. S.; Chuang, D. M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 2007, 321, 892-901.
91. Mishra, N.; Brown, D. R.; Olorenshaw, I. M.; Kammer, G. M. Trichostatin A reverses skewed expression of CD 154, interleukin, and interferon- gene and protein expression in lupus T cells. Proc. Nat. Acad. Sci. 2001, 98, 2628-2633.
92. Reily, C. M.; Mishra, N.; Miller, J. M.; Joshi, D.; Ruiz, P.; Richon, V. M.; Marks, P. A.; Gilkeson, G. S. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J. Immunol. 2004, 173, 4171-4178.
93. Mishra, N.; Reilly, C. M.; Brown, D. R.; Ruiz, P.; Gilkeson, G. S. Histone deacetylase inhibitors modulate renal disease in the MRL-1pr/1pr mouse. J. Clin. Invest. 2003, 111, 539-552.
94. Garcia, B. A.; Busby, S. A.; Shabanowitz, J.; Hunt, D. F.; Mishra, N. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition.. J. Proteome Res. 2005, 4, 2032-2042.
95. Pomerantz, R. J. Reservoirs, sanctuaries and residual disease: the hiding spots of HIV-1. HIV Clin. Trials 2003, 4, 137-143.
96. Richman, D. D.; Margolis, D. M.; Delaney, M.; Greene, W. C.; Hazuda, D.; Pomerantz, R. J. The Challenge of Finding a Cure for HIV Infection. Science 2009, 323, 1304-1307.
97. Williams, S. A.; Chen, L. F.; Kwon, H.; Ruiz-Jarabo, C. M.; Verdin, E.; Greene, W. C. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 2007, 25, 139-149.
98. Lehrman, G.; Hogue, I. B.; Palmer, S.; Jennings, C.; Spina, C. A.; Wiegand, A.; Landay, A. L.; Coombs, R. W.; Richman, D. D.; Mellors, J. W. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366, 549-555.
99. Contreras, X.; Schewwnker, M.; Chen, C.-S.; McCune, J. M.; Deeks, S. G.; Martin, J.; Peterlin, B. M. Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells. J. Biol. Chem. 2009, 284, 6782-6789.
100. Kwon, H. J.; Kim, J. H.; Kim, M.; Lee, J. K.; Hwang, W. S.; Kim, D. Y. Anti-parasitic activity of depudecin on Neospora caninum via the inhibition of histone deacetylase. Vet. Parasitol. 2003, 112, 269-276.
101. Darkin-Rattray, S. J.; Gurnett, A. M.; Myers, R. W.; Dulski, P. M.; Crumley, T. M.; Allocco, J. J.; Cannova, C.; Meinke, P. T.; Colletti, S. L.; Bednarek, M. A. Apicidin: a novel anti-protozoal agent that inhibits parasite histone deactylase. Proc. Nat. Acad. Sci. 1996, 93, 13143-13147.
102. Colletti, S. L.; Meyers, R. W.; Darkin-Rattray, S. J.; Gurnett, A. M.; Dulski, P. M.; Galuska, S.; Allocco, J. J.; Ayer, M. B.; Li, C.; Lim, J.; Crumley, T. M.; Cannova, C.; Schmatz, D. M.; Wyvratt, M. J.; Fisher, M. H.; Meinke, P.T. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure activity relationships of Apicidin. Part 2.. Bioorg. Med. Chem. Lett. 2001, 11, 113-117.
103. Andrews, K. T.; Walduck, A.; Kelso, M. J.; Fairlie, D. P.; Saul, A.; Parson, P. G. Anti-malarial effect of histone deacetylation inhibitors and mammalian tumor cytodifferentiating agents. Int. J. Paristol. 2000, 30, 761-768.
104. Andrews, K. T.; Tran, T. N.; Lucke, A. J.; Kahnberg, P.; Le, G. T.; Boyle, G. M.; Gardiner, D. L.; Skinner-Adams, T. S.; Fairlie, D. P. Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob. Agents Chemother. 2008, 52, 1454-1461.
105. Dow, G. S.; Chen, Y.; Andrews, K. T.; Caridha, D.; Gerena, L.; Gettayacamin, M.; Johnson, J.; Li, Q.; Melendez, V.; Obalda, N. Activity in phenylthiazoyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob. Agents Chemother. 2008, 52. 3467-77
106. Choi, J. H.; Kang, M. S.; Kwon, H. J.; Oh, G. T.; Kim, D. Y. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin. Exp. Allergy 2005, 35, 89-96.
107. Burrows, J. A. J.; Willis, L.; Perlmutter, D. H. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT)Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Nat. Acad. Sci. 2000, 97, 1796-1801.
108. Mai, A.; Rotili, D.; Massa, S.; Brosch, G.; Simonetti, G.; Passariello, C.; Palamara, A. T. Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. Bioorg. Med. Chem. Lett. 2007, 17, 1221-1225.
109. Herman, D.; Jenssen, K.; Burnett, R.; Sorangi, E.; Perlman, S. L.; Gottesfeld, J. M. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2006, 2, 551-558.
110. Vecsey, C. G.; Hawk, J. D.; Lattal, K. M.; Stein, J. M.; Fabian, S. A.; Attner, M. A.; Cabrera, S. M.; McDonough, C. B.; Brindle, P. K.; Abel, T.; Wood, M. A. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation. J. Neurosci. 2007, 27, 6128-6140.
111. Camelo, S.; Iglesias, A. H.; Hwang, D.; Due, B.; Ryu, H.; Smith, K.; Gray, S. G.; Imitola, J.; Duran, G.; Assaf, B.; Langley, B.; Khoury, S. J.; Stephanopoulos, G.; De Girolami, U.; Ratan, R. R.; Ferrante, R. J.; Dangond, F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164, 10-21.
112. Kim, S.-J.; Lee, B.-H.; Lee, Y.-S.; Kang, K.-S. Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann-Pick type C disease improved by valproic acid, a histone deacetylase inhibitor. Biochem. Biophys. Res. Commun. 2007, 360, 593-599.
113. Reddy, P.; Maeda, Y.; Hotary, K.; Liu, C.; Reznikov, L. L.; Dinarello, C. A.; Ferrara, L. M. Histone deacetylase inhibitor for suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Nat. Acad. Sci. 2004, 101, 3921-3926.
114. Reddy, P.; Sun, Y.; Toubai, T.; Duran-Struuck, R.; Clouthier, S. G.; Weisiger, E.; Maeda, Y.; Tawara, I.; Krijanovski, O.; Gatza, E.; Liu, C.; Malter, C.; Mascagni, P.; Dinarello, C. A.; Ferrara, J. L. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 2008, 118, 2562-2569.
115. McLaughlin, F.; La Thangue, N. B. Histone deacetylase inhibitors in psoriasis therapy. Curr. Drug Targets Inflamm. Allergy 2004, 3, 213-219.
116. Yasukawa, K.; Sawamura, D.; Goto, M.; Nakamura, H.; Shimizu, H. Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts. Br. J. Dermatol. 2007, 157, 662-669.
117. Moreira, J. M.; Scheipers, P.; Sørensen, P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 2003, 3, 30.
118. Leoni, F.; Zaliani, A.; Bertolini, G.; Porro, G.; Pagani, P.; Pozzi, P.; Donà, G.; Fossati, G.; Sozzani, S.; Azam, T.; Bufler, P.; Fantuzzi, G.; Goncharov, I.; Kim, S. H.; Pomerantz, B. J.; Reznikov, L. L.; Siegmund, B.; Dinarello, C. A.; Mascagni, P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Nat. Acad. Sci. 2002, 99, 2995-3000.
119. Chung, Y. L.; Lee, M. Y.; Wang, A. J.; Yao, L. F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Therap. 2003, 8, 707-717.
120. Rombouts, K.; Niki, T.; Greenwel, P.; Vandermonde, A.; Wielant, A.; Hellemans, K.; De Blesser, P.; Yoshida, M.; Schuppen, D.; Rojkind, M.; Geerts, A. Trichostatin A, a histone deacetylase inhibitor, supresses collagen synhthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp. Cell Res. 2002, 278, 184-197.
121. Wu, Y.; Guo, S. W. Suppression of IL-1beta COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells. Eur. J. Obstet. Gynecol. Reprod. 2007, 135, 88-93.
122. Moynihan, A.; Hehir, M.; Sharkey, A. Histone deacetylase inhibitors and a functional potent inhibitory effect on human uterine contractility. Am. J. Obstet. & Gynecol. 2008, 199, 167.e1-167.e7.
123. Sun, C.; Zhou, J. Trichostatin A improves insulin stimulated glucose utilization and insulin signaling transduction through the repression of HDAC2. Biochem. Pharmacol. 2008, 76, 120-127.
124. McCaffrey, P. G.; Newsome, D. A.; Fibach, E.; Yoshida, M.; Su, M. S.-S. Induction of γ-globin by histone deacetylase inhibitors. Blood 1997, 90, 2075-2083.
125. Rubenstein, R. C.; Zeitlin, P. L. A pilot clinical trial of sodium phenylbutyrate (Buphenyl) in delta F508-homozygous cystic fibrotic patients: evidence of restoration of nasal epithelial CFTR function. Am. J. Resp. Crit. Care 1998, 157, 484-490.
126. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-call lymphoma. Oncologist 2007, 12, 1247-1252.
127. Weisburger, J. H.; Weisburger, E. K. Biochemical formation and pharmacological, and toxicological, and pathological properties of hydroxylamines and hydroxamic acids. Pharmacol. Rev. 1973, 25, 1-66.
128. Belvisi, M. G.; Bottomley, K. M. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm. Res. 2003, 52, 95-100.
129. Wise, L. D.; Turner, K. J.; Kerr, J. S. Assessment of developmental toxicity of vorinostat, histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res. B Dev. Reprod. Toxicol. 2007, 80, 57-68.
130. Wise, L. D.; Spence, S.; Sidutti, L. P.; Kerr, J. S. Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhinbitor. Birth Defects Res. B. Dev. Reprod Toxicol. 2008, 83, 19-26.
131. Roy, S.; Tenniswood, M. Site-specific acetylation of p53 directs selective transcription complex assembly. J. Biol. Chem. 2007, 282, 4765-4771.
132. Roy, S.; Jeffrey, R.; Tenniswood, M. Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells. Mol. Cancer Ther. 2009, 7, 1931-1939.
133. Schroeder, T. M.; Nair, A. K.; Staggs, R.; Lamblin, A.-F.; Westendorf, J. J. Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors. BMC Genomics 2007, 8, 362.
134. Qui, L.; Burgess, A.; Fairlie, D. P.; Leonard, H.; Parsons, P. G.; Gabrielli, B. G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell 2000, 11, 2069-2083.
135. Burgess, A.; Ruefli, A.; Beamish, H.; Warrener, R.; Saunders, N.; Johnstone, R. W.; Gabrielli, B. G. Histone deacetylase inhibitors specifically kill nonproliferating tumor cells. Oncogene 2004, 23, 6693-6701.
136. Sandor, V.; Baake, S.; Robey, R.; Kang, M. H.; Blagosklonny, M. V.; Bender, J.; Brooks, R.; Piekarz, R. L.; Tucker, E.; Figg, W. D.; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; SE., B. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.. Clin. Caner Res. 2002, 8, 718-728.
137. Molife R; Fong P; Scurr M; Judson I; Kaye S; J., d. B. HDAC inhibitors and cardiac safety. Clin. Cancer Res. 2007, 13, 1068.
138. Shah, M. H.; Binkley, P.; Chan, K.; Xiao, J.; Arbogast, D.; Collamore, M.; Farra, Y.; Young, D.; Grever, M. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 2006, 12, 3997-4003.
139. Estiu, G.; Greenberg, E.; Harrison, C. B.; Kwiatkowski, N. P.; Mazitschek, R.; Bradner, J. E.; Wiest, O. Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors. J. Med. Chem. 2008, 51, 2898-2906.
140. Weerasinghe, S. V. W.; Estiu, G.; Wiest, O.; Pflum, M. K. Residues in the 11Å Channel of Histone Deacetylase 1 Promote Catalytic Activity: Implications for Designing Isoform-Selective HDAC inhibitors. J. Med. Chem. 2008, 51, 5543-5551.
141. Gimsing, P.; Hansen, M.; Knudsen, L. M.; Knoblauch, P.; Christensen, I. J.; Ooi, C. E.; Buhl-Jensen, P. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 2008, 81, 170-176.
142. Steele, N. L.; Plumb, J. A.; Vidal, L.; Tjornelund, J.; Knoblauch, P.; Rasmussen, A.; Ooi, C. E.; Buhl-Jensen, P.; Brown, R.; Evans, T. R.; JS. D. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 804-810.
143. Gore, L.; Rothenberg, M. L.; O'Bryant, C. L.; Schultz, T. K.; Sandler, A. B.; Coffin, D.; McCoy, C.; Schott, A.; Scholz, C.; Eckhardt, S. G. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 2007, 14, 4517-4525.
144. Siu, L. L.; Pili, R.; Messersmith, W. A.; Chen, E. X.; Sullivan, R.; MacLean, M.; King, S.; Brown, S.; Reid, G. K.; Li, Z.; Kalita, A. M.; Laille, E. J.; Besterman, J. M.; Martell, R. E.; Carducci, M. A. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26, 1940-1947.
145. Bieliauskas, A. V.; Pflum, M. K. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 2008, 37, 1402-1413.
146. Bhaumik, S. R.; Smith, E.; Shilatifard, A. Covalent modifications of
147. Wang, D.-F.; Helquist, P.; Wiech, N.; Wiest, O. Toward selective histone deacetylase inhibitor design. Homology modeling, docking studies and molecular dynamic simulations of human class I histone deacetylases. J. Med. Chem. 2005, 48, 6936-6947.
148. Wang, D.-F.; Wiest, O.; Helquist, P.; Lan-Hargest, H.-Y.; Wiech, N. On the Function of the 14 A Long Internal Cavity of Histone Deacetylase-Like Protein: Implications for the Design of Histone Deacetylase Inhibitors. J. Med. Chem. 2004, 47, 3409-3417.